UPL Limited Annual Secretarial Compliance Report Released for FY 2025-26

UPL Limited has officially released its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, verified by N. L. Bhatia & Associates, confirms that the company has adhered to all necessary corporate governance standards and statutory requirements during the review period. The findings validate the firm’s ongoing commitment to transparent operations and robust management systems.

Commitment to Corporate Governance

UPL Limited has successfully completed its annual audit process regarding secretarial compliance. The review was conducted by the firm N. L. Bhatia & Associates, who assessed the company’s internal systems, record-keeping, and adherence to prescribed guidelines throughout the 2025-26 fiscal year.

Key Findings of the Review

The audit covered a comprehensive verification of documentation, filings with relevant authorities, and public disclosures. The report confirms that the company maintains fully functional and compliant systems. Key areas assessed include:

  • Strict adherence to corporate secretarial standards.
  • Timely adoption and updates of all necessary internal policies.
  • Maintenance of transparent and accurate disclosures on the official company website.
  • Verification that all directors meet the required eligibility criteria under the Companies Act.
  • Robust oversight of related party transactions and material subsidiaries.

Operational Integrity

The auditors concluded that there were no deviations or non-compliances observed during the period ending March 31, 2026. Furthermore, the company has effectively maintained records as prescribed by current policies and has conducted performance evaluations for its Board and Committees as required. This clean audit report reflects UPL’s high standard of operational discipline and regulatory compliance.

Source: BSE

Previous Article

Jindal Stainless Unveiling Growth Strategy and Record Performance in Corporate Presentation

Next Article

Gland Pharma Limited Reports Strong Revenue and Profit Growth for FY26